Skip to main content
Caplight Logo









Open Therapeutics

Open Therapeutics

Private
Minneapolis, MinnesotaHealthcare & Life Scienceshttps://opentherapeutics.org/

Last Round

Grant

Nov 8, 2022

Company Overview

Open Therapeutics is a biotechnology company that curates and develops open-source medical, biopharma, and synthetic biology-based technologies for the global scientific community.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Blockchain Infrastructure, Tokenization

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service, Revenue Share

AI Layer

Non-AI

Keywords

open-source biotechnologyopen sciencedrug discoverybiopharma researchsynthetic biologytherapeutic intellectual propertydecentralized scienceDeSciresearch crowdsourcingpeer review platformcryptocurrency incentivetokenized researchscientific collaborationbiotech consultingintellectual property licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Open Therapeutics Comparables

Compare Open Therapeutics with similar companies based on industry and business-model similarity.

Open Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
ResearchHub
83%
Open Source Pharma Foundation
82%
Etica Protocol
77%

Open Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantNov 8, 2022
Early FundingFeb 19, 2019

Open Therapeutics Investors

Notable investors and investment history

Open Therapeutics investors
InvestorRounds
Timmaron GroupEarly Funding

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 8, 2022

    Received grant funding.

  • Feb 19, 2019

    Raised capital with participation from Timmaron Group.

Open Therapeutics Filings

Explore SEC and related filing metadata, where available.

Open Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Open Therapeutics's valuation, stock price, and market status.

Is Open Therapeutics a public or private company?

Open Therapeutics is a private company.

What is the current stock price of Open Therapeutics?

Open Therapeutics is a private company with no public stock price. Caplight tracks Open Therapeutics's secondary market activity and provides MarketPrice™ estimates to Caplight users.

How much is Open Therapeutics worth (valuation)?

Valuation information for Open Therapeutics is not publicly available.

Can I buy Open Therapeutics stock?

Open Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Open Therapeutics's last funding round?

Open Therapeutics's most recent funding round was Grant on November 8, 2022.

Who are the main investors in Open Therapeutics?

Key investors in Open Therapeutics include Timmaron Group.

Will Open Therapeutics IPO soon?

No public IPO plans have been announced for Open Therapeutics.

How can I track Open Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Open Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersMinneapolis, Minnesota
Year Founded2009
Last FundingNov 8, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?